The Drug Holiday That Doesn't End: How PEPFAR Cuts Are Pulling Young Kenyans Off Their HIV Drugs

In the long, single-storey clinic block of Mathare North on a Monday morning, a 24-year-old man checks his phone for the third time. He has been on antiretroviral therapy since he was 14. He has not picked up his refill in five weeks. The pharmacy queue is shorter than he remembers from last year. So is the line for counselling. The youth-friendly room at the end of the corridor — the one painted with a mural of a sunrise — is locked.

What is unfolding inside Kenya's HIV treatment system is not loud, and it is not televised. It is the quiet sound of pills not being collected. A new clinical study reported in Nairobi this week confirms what nurses and lay counsellors have been whispering for months: young Kenyans living with HIV are stepping away from their medication in growing numbers, and the structures that used to catch them are gone or going.

For the Kenyan diaspora — the aunts in Baltimore who wire the cost of a CD4 test, the cousins in Manchester who keep a private WhatsApp group called "Mama's medicine" — this is no longer abstract. The American aid architecture that paid for much of Kenya's HIV response has been substantially withdrawn, and the rebound is showing up at the dispensary window.

A new study, a familiar crisis

The Daily Nation reported this week on findings from a Nairobi-based clinical research team that mapped adherence among young people on ARVs across the capital. The pattern is stark. Those living more than ten kilometres from a treatment facility were significantly more likely to skip medication. Those who used alcohol or other substances were roughly three times as likely to miss doses or appointments. Patients diagnosed in adulthood — rather than at birth — were four times as likely to miss clinic appointments, a gap researchers tied to the psychological weight of a late diagnosis and the stigma that still clings to it.

The most striking finding was the simplest. People without an active support group were nearly 1.7 times more likely to default. Solidarity, the study suggested, may be doing more work in Kenya's HIV outcomes than any single drug regimen.

The reporting traces personal arcs. A young man called Juma has not taken his medication for two weeks. A young woman called Gabriella dropped to 46 kilograms before her parents discovered her secret. A patient named Taylor stayed adherent for six months and then surrendered to what the youth clinics now openly call pill fatigue. Another, Keylor, defaulted three times over several years; once, he was pulled back to the clinic only because tuberculosis put him there.

These are individual stories, but they sit on top of a national curve that has shifted.

When the refills stop coming

For two decades, Kenya operated a quiet miracle. With one of the highest HIV burdens in the world, the country built dense networks of treatment sites, peer educators, mentor mothers, and youth-only clinics that allowed adolescents to walk in past the gossip of an older waiting room. The model was not perfect. It was, in many corners, extraordinary.

Much of that infrastructure was paid for by the United States. The President's Emergency Plan for AIDS Relief, better known as PEPFAR, has been the single largest external financier of Kenya's HIV response for years. Public-health officials in Nairobi have estimated that external partners cover roughly two-thirds of the country's HIV bill, with PEPFAR doing the heaviest lifting on care, treatment, and prevention.

When the Trump administration's foreign-aid freeze of early 2025 hit, that scaffolding began to creak. A presidential executive order paused new disbursements for ninety days, and a subsequent rescissions package codified deeper cuts. The DREAMS programme — designed to keep adolescent girls and young women HIV-free — was wound down in the ten countries where it had operated, including Kenya. Outreach to so-called key populations was disrupted. PrEP supply chains stuttered. UNAIDS warned within weeks that testing and treatment numbers were already sliding.

Dr Samuel Kinyanjui of the AIDS Healthcare Foundation, quoted in the Nation piece, put it plainly. Without mentorship or programmes like OTZ and DREAMS, he said, many young people drift from life-saving regimens. They call it a treatment break. The growing trend of self-prescribed drug holidays, he added, is dangerously unsafe.

The American hand on a Kenyan pillbox

It is tempting in Nairobi political circles to frame the PEPFAR cuts as an act of distant Washington bureaucracy. Inside the diaspora — particularly in Baltimore, Atlanta, Houston, and the Kenyan corridors of northern New Jersey — the picture is more uncomfortable. PEPFAR was an American gift, but it was also an American responsibility, and many Kenyan-American clinicians, nurses, and pastors built their professional and pastoral lives around the assumption that it would persist.

A nurse at a Kenyan-led clinic in suburban Atlanta described, in a community webinar last month, spending part of every shift fielding messages from siblings back home asking whether refills will run out. A Kenyan-American doctor in Greater London described colleagues quietly pooling money to keep a relative on second-line therapy for the next ninety days. None of this is illegal. Most of it is invisible. All of it points to a shift: a public-health system that used to be largely managed by international partners is now being subsidised, in cash, by the diaspora.

That subsidy cannot scale to replace PEPFAR. A million-dollar gap in a clinic budget cannot be closed by a mobile-money transfer from Maryland. But the diaspora has always been Kenya's quietest middle class, and the new arithmetic — fewer outreach workers, longer queues, locked-up youth clinics — is forcing many of them to learn, for the first time, what their relatives actually pay for treatment.

What the silence looks like

The medical fallout is real. When a patient stops taking ARVs, the virus is not patient with them. Viral load rises, CD4 cells fall, and HIV can mutate into drug-resistant strains, rendering Kenya's cheap, effective first-line regimens useless. Switching a patient to second-line drugs costs the public system several times more, and supply chains for those medicines are themselves under pressure as donor budgets tighten.

The political fallout is slower. Kenya's Ministry of Health has promised a five-to-ten percent increase in its domestic HIV budget for 2026, but officials privately concede that this is not enough to compensate for the withdrawal. Civil-society groups have begun to lobby Parliament for ring-fenced funding. President William Ruto's government, already navigating a fuel-price crisis and renewed scrutiny over the cost of living, has so far been cautious about pledging more.

In the meantime, the youth-friendly clinic in Mathare North stays locked on most afternoons. The mural of the sunrise is fading. The 24-year-old man on the bench does not yet know whether he will pick up his refill today. He has a brother in Texas who has started messaging him every Friday — short, anxious texts that say only, "Did you go?"

For Kenya's HIV response, that text message is now part of the treatment plan.